CAMP4 Therapeutics Corporation Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
CAMP4 Therapeutics Corporation (CAMP) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$1.82 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-13
- CAMP4 Therapeutics Corporation increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was -$453.00K, a 143.94% decline year-over-year.
- CAMP4 Therapeutics Corporation increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$1.37M.
- CAMP4 Therapeutics Corporation increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $1.20M, a 34.93% decline year-over-year.
- CAMP4 Therapeutics Corporation increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was $1.36M, a 89.96% increase year-over-year.
- CAMP4 Therapeutics Corporation increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was $805.00K, a 47.42% decline from fiscal 2024.
- CAMP4 Therapeutics Corporation increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was $1.53M.
- CAMP4 Therapeutics Corporation increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was -$136.00K.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$453.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$1.82M 10-Q · filed 2026-08-13 | -$624.00K derived: sum of 3 quarters · filed 2026-08-13 | $738.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$1.37M 10-Q · filed 2026-05-07 | -$171.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.19M derived: sum of 3 quarters · filed 2026-05-07 | $2.22M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $2.56M derived: sum of 2 quarters · filed 2026-03-05 | $3.59M derived: sum of 3 quarters · filed 2026-08-13 | $805.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | $1.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.39M derived: sum of 2 quarters · filed 2026-08-13 | -$393.00K 10-Q · filed 2025-11-06 | $1.45M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $1.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$1.75M 10-Q · filed 2026-08-13 | $86.00K derived: sum of 3 quarters · filed 2026-08-13 | $803.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$2.79M 10-Q · filed 2026-05-07 | -$945.00K derived: sum of 2 quarters · filed 2026-05-07 | -$228.00K derived: sum of 3 quarters · filed 2026-05-07 | -$1.70M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $2.56M derived: sum of 2 quarters · filed 2026-03-05 | $1.08M derived: sum of 3 quarters · filed 2026-03-05 | $1.53M 10-K · filed 2026-03-05 |
| 2024-09-30 | $717.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$758.00K derived: sum of 2 quarters · filed 2025-11-06 | -$310.00K 10-Q · filed 2025-11-06 | $252.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$1.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$1.03M 10-Q · filed 2025-08-14 | -$465.00K derived: sum of 3 quarters · filed 2025-08-14 | |
| 2024-03-31 | $448.00K 10-Q · filed 2025-05-13 | $1.01M derived: sum of 2 quarters · filed 2025-05-13 | ||
| 2023-12-31 | $562.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$136.00K 10-K · filed 2025-03-27 | ||
| 2023-09-30 | -$698.00K 10-Q · filed 2024-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |